(RS)-ketoprofen

Overview

(RS)-ketoprofen is a racemic non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid class, structurally and pharmacologically related to ibuprofen and naproxen. It exerts its primary therapeutic effects through non-selective inhibition of cyclooxygenase (COX-1 and COX-2) enzymes, thereby suppressing the biosynthesis of prostaglandins—including prostaglandin E2—and thromboxanes from arachidonic acid. This mechanism underlies its analgesic, antipyretic, and anti-inflammatory properties. The racemic designation "(RS)" reflects the presence of both the pharmacologically active (S)-enantiomer and the less active (R)-enantiomer, a characteristic shared with several propionic acid NSAIDs and relevant to its pharmacokinetic and pharmacodynamic profile. ketoprofen is metabolized primarily by the hepatic enzyme cytochrome P450 2C9 (CYP2C9), making it susceptible to clinically significant drug–drug interactions and genotype-dependent variability in exposure.

Clinically, ketoprofen is used for the management of pain and inflammation in conditions such as arthritis, postoperative pain, and musculoskeletal disorders. Beyond its established role as a systemic and topical anti-inflammatory agent, it has attracted growing interest as a candidate for advanced drug delivery systems and as part of multimodal analgesic regimens. Its relatively well-characterized pharmacology and metabolic pathway have also made it a valuable probe drug in pharmacokinetic research, particularly for CYP2C9 phenotyping and inhibition studies.

Focus of Latest Publications

Recent literature reflects a broad and diversified research interest in ketoprofen, spanning oncology, drug delivery engineering, environmental science, pharmacokinetic modelling, periodontal therapy, and perioperative medicine.

Anticancer and Combination Therapy Contexts

A 2026 study published in Artificial Cells, Nanomedicine, and Biotechnology evaluated ketoprofen alongside sulindac, celecoxib, and the antidepressant fluoxetine—both in free form and conjugated with Janus dendrimers—for in vitro anticancer activity against MCF-7 (human breast adenocarcinoma) and SK-LU-1 (human lung adenocarcinoma) cell lines, with COS-7 normal monkey kidney cells serving as a control. This work positioned ketoprofen within the emerging paradigm of NSAID repurposing for oncology, where its COX-mediated suppression of pro-tumorigenic prostaglandin E2 and downstream inflammatory mediators such as C-C motif chemokine ligand 2 and matrix metalloproteinase-9 may contribute to anti-proliferative and pro-apoptotic effects.

Advanced Drug Delivery Systems

A significant focus of current research concerns overcoming the physicochemical limitations of ketoprofen—including its moderate aqueous solubility—through novel formulation strategies. A 2026 study in Pharmaceutical Development and Technology developed and optimized ketoprofen-loaded solid lipid nanoparticles (SLNs) using a mixture design approach, evaluating their performance in topical anti-inflammatory applications via a carrageenan-induced rat paw edema model. The SLN formulations were designed to augment the drug's bioavailability and localized efficacy, demonstrating the continued relevance of nanoparticle platforms for NSAID delivery. Separately, research published in ACS Applied Bio Materials (2026) explored core-shell electrospun membranes for periodontal therapy, in which ketoprofen was specifically loaded into the shell layer to enable localized, controlled anti-inflammatory release, complementing antimicrobial agents in the core. This bilayer architecture reflects a sophisticated understanding of the spatial and temporal requirements for resolving periodontitis-associated inflammation.

In the domain of personalized medicine, a 2026 study in the European Journal of Pharmaceutical Sciences demonstrated that fused deposition modeling (FDM) 3D printing using polyvinyl alcohol (PVA) could produce ketoprofen capsule shells with tunable release profiles—spanning immediate, sustained, and delayed release—supported by in silico pharmacokinetic modeling. A dual-compartment polypill combining ketoprofen with famotidine was also produced, addressing the well-recognized gastrointestinal liability of NSAIDs.

Pharmacokinetic and Drug–Drug Interaction Research

ketoprofen's role as a CYP2C9 probe drug was examined in a 2026 model-based pharmacokinetic analysis published in the British Journal of Pharmacology, which characterized the effects of CYP2C9 genotype on fluconazole-mediated enzyme inhibition using flurbiprofen, ketoprofen, and tolbutamide as probe substrates. This study underscored ketoprofen's suitability as a phenotyping tool for CYP2C9 activity and highlighted how genetic polymorphisms in CYP2C9 can modify the magnitude of inhibitory drug interactions—a clinically important consideration when ketoprofen is co-administered with azole antifungals or other CYP2C9 inhibitors.

Perioperative Pain Management

A real-world cohort study leveraging large language models to audit perioperative care in total laryngectomy patients (Otolaryngologia Polska, 2026) reported that intravenous ketoprofen was employed as part of multimodal analgesic protocols in 47% of patients, alongside paracetamol (60%) and metamizole (40%), with strong opioids required in only 5% of cases. This finding reinforces ketoprofen's established utility in opioid-sparing analgesic strategies in the perioperative setting.

Environmental Persistence

Beyond its clinical and pharmaceutical dimensions, ketoprofen has been identified as an environmental micropollutant of concern. A 2026 study in Environmental Technology assessed the removal of ketoprofen alongside Diclofenac, indomethacin, mefenamic acid, ibuprofen, and naproxen in laboratory-scale hybrid biofilm reactors operating under low organic loading conditions. ketoprofen achieved a removal efficiency of 91.4%, representing one of the lower removal rates among the NSAIDs studied, highlighting its relative persistence in biological wastewater treatment systems and the need for optimized reactor conditions to address pharmaceutical micropollutant loads.

Key Publications

NEWJun Response of microbial interactions in hybrid biofilm system with low organic loading to micropollutant removal. (Environmental technology, 2026, PMID 42093172): "Significant removal efficiencies for ibuprofen (99.7%), indomethacin (99.0%), naproxen (97.6%), mefenamic acid (97%), and ketoprofen (91.4) were achieved."
May Leveraging large language models to audit perioperative total laryngectomy care: anesthetic, nutritional, and complication profiles in a real‑world cohort. (Otolaryngologia polska = The Polish otolaryngology, 2026, PMID 42178846): "Multimodal analgesia based on intravenous paracetamol (60%), ketoprofen (47%), and metamizole (40%) was routinely employed, while strong opioids were used in only 5% of patients."
May Anticancer activity of fluoxetine Janus dendrimer against cancer cells. (Artificial cells, nanomedicine, and biotechnology, 2026, PMID 42167254): "We evaluated the in vitro anticancer effects of sulindac, ketoprofen, celecoxib and the antidepressant fluoxetine, both free and coupled with synthesized dendrons and dendrimers, on the proliferation and apoptosis of human MCF-7 (human mammary adenocarcinoma), SKLU-1 (human lung adenocarcinoma) and as a control the normal monkey kidney (COS-7) cell line."
May Core-Shell Electrospun Membranes Enable Antimicrobial and Immunomodulatory Local Therapy for Periodontitis. (ACS applied bio materials, 2026, PMID 41988912): "while ketoprofen was loaded in the shell for localized anti-inflammatory delivery."
May Mixture Design-Modelling and Optimization of Ketoprofen Solid Lipid Nanoparticles for Augmented Anti-inflammatory Activity Following Pharmacodynamic Evaluation in Rats. (Pharmaceutical development and technology, 2026, PMID 42133922): "The present study aimed to formulate and optimize ketoprofen (KP)-loaded SLNs to enhance the drug's therapeutic efficacy in topical inflammatory conditions."
May A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs. (British journal of pharmacology, 2026, PMID 41566662): "A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs."
May Personalized oral drug delivery via FDM 3D printing: Polyvinyl alcohol capsules with tunable release profiles supported by in silico modeling. (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026, PMID 41702496): "Ketoprofen was formulated into FDM-printed polyvinyl alcohol (PVA) capsule shells which were subsequently filled with ketoprofen powder and locked to form complete 3D‐printed capsules, spanning immediate-, sustained-, and delayed-release designs; a dual-compartment polypill with famotidine was also produced."